Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary centre in the USA.

Sofjan AK, Musgrove RJ, Beyda ND, Russo HP, Lasco TM, Yau R, Restrepo A, Garey KW.

J Glob Antimicrob Resist. 2018 Dec;15:41-47. doi: 10.1016/j.jgar.2018.05.015. Epub 2018 May 26.

PMID:
29842975
2.

Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital.

Abodakpi H, Chang KT, Sánchez Díaz AM, Cantón R, Lasco TM, Chan K, Sofjan AK, Tam VH.

J Chemother. 2018 Apr;30(2):115-119. doi: 10.1080/1120009X.2017.1399233. Epub 2017 Nov 10.

PMID:
29125052
3.

Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.

Skoglund E, Ledesma KR, Lasco TM, Tam VH.

J Glob Antimicrob Resist. 2017 Dec;11:154-155. doi: 10.1016/j.jgar.2017.10.016. Epub 2017 Oct 31. No abstract available.

PMID:
29101084
4.

Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline.

Chen A, Smith KP, Whitfield BA, Zucchi PC, Lasco TM, Bias TE, Kirby JE, Hirsch EB.

Diagn Microbiol Infect Dis. 2017 Aug;88(4):365-367. doi: 10.1016/j.diagmicrobio.2017.05.004. Epub 2017 May 11.

PMID:
28535946
5.

Disseminated coccidioidomycosis with multifocal musculoskeletal disease involvement.

McConnell MF, Shi A, Lasco TM, Yoon L.

Radiol Case Rep. 2016 Dec 23;12(1):141-145. doi: 10.1016/j.radcr.2016.11.017. eCollection 2017 Mar.

6.

Outcomes and Risk Factors for Mortality among Patients Treated with Carbapenems for Klebsiella spp. Bacteremia.

Biehle LR, Cottreau JM, Thompson DJ, Filipek RL, O'Donnell JN, Lasco TM, Mahoney MV, Hirsch EB.

PLoS One. 2015 Nov 30;10(11):e0143845. doi: 10.1371/journal.pone.0143845. eCollection 2015.

7.

Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests.

Nesher L, Hadi CM, Salazar L, Wootton SH, Garey KW, Lasco T, Luce AM, Hasbun R.

Epidemiol Infect. 2016 Jan;144(1):189-97. doi: 10.1017/S0950268815000850. Epub 2015 May 20.

PMID:
25989841
8.

Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples.

Kilic A, Alam MJ, Tisdel NL, Shah DN, Yapar M, Lasco TM, Garey KW.

Ann Lab Med. 2015 May;35(3):306-13. doi: 10.3343/alm.2015.35.3.306. Epub 2015 Apr 1.

9.

Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship.

Aitken SL, Hemmige VS, Koo HL, Vuong NN, Lasco TM, Garey KW.

Diagn Microbiol Infect Dis. 2015 Jan;81(1):4-8. doi: 10.1016/j.diagmicrobio.2014.09.025. Epub 2014 Oct 2.

PMID:
25445120
10.

Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas.

Aitken SL, Joseph TB, Shah DN, Lasco TM, Palmer HR, DuPont HL, Xie Y, Garey KW.

PLoS One. 2014 Jul 24;9(7):e102848. doi: 10.1371/journal.pone.0102848. eCollection 2014.

11.

FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.

Beyda ND, John J, Kilic A, Alam MJ, Lasco TM, Garey KW.

Clin Infect Dis. 2014 Sep 15;59(6):819-25. doi: 10.1093/cid/ciu407. Epub 2014 May 30.

PMID:
24879785
12.

Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates.

Koo HL, Van JN, Zhao M, Ye X, Revell PA, Jiang ZD, Grimes CZ, Koo DC, Lasco T, Kozinetz CA, Garey KW, DuPont HL.

Infect Control Hosp Epidemiol. 2014 Jun;35(6):667-73. doi: 10.1086/676433. Epub 2014 Apr 22.

PMID:
24799643
13.

Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics.

Aitken SL, Beyda ND, Shah DN, Palmer HR, Lasco TM, Koo H, Garey KW.

Ann Pharmacother. 2014 Jun;48(6):683-90. doi: 10.1177/1060028014529928. Epub 2014 Mar 31.

PMID:
24687545
14.

An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.

Hirsch EB, Chang KT, Zucchi PC, Francoeur DN, Ledesma KR, Tam VH, Lasco TM.

J Infect Chemother. 2014 Mar;20(3):224-7. doi: 10.1016/j.jiac.2013.10.011. Epub 2013 Dec 11.

PMID:
24674388
15.

Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.

Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL.

Antimicrob Agents Chemother. 2013 Jun;57(6):2690-3. doi: 10.1128/AAC.00548-13. Epub 2013 Apr 1.

16.

Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic.

McGrath DM, Barbu EM, Driessen WH, Lasco TM, Tarrand JJ, Okhuysen PC, Kontoyiannis DP, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3477-82. doi: 10.1073/pnas.1221924110. Epub 2013 Jan 23.

17.

Physician attitudes toward the use of fecal transplantation for recurrent Clostridium difficile infection in a metropolitan area.

Jiang ZD, Hoang LN, Lasco TM, Garey KW, Dupont HL.

Clin Infect Dis. 2013 Apr;56(7):1059-60. doi: 10.1093/cid/cis1025. Epub 2012 Dec 7. No abstract available.

PMID:
23223589
18.

Correlation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteria.

Tam VH, Hirsch EB, Lasco TM, Gentry LO, Palmer HR.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1120-2. doi: 10.1345/aph.1R021. Epub 2012 Jul 3. No abstract available.

PMID:
22764323
19.

Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia.

Shah DN, Yau R, Lasco TM, Weston J, Salazar M, Palmer HR, Garey KW.

Antimicrob Agents Chemother. 2012 Jun;56(6):3239-43. doi: 10.1128/AAC.00019-12. Epub 2012 Mar 12.

20.

Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes.

Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, Garey KW.

J Antimicrob Chemother. 2011 Sep;66(9):2146-51. doi: 10.1093/jac/dkr244. Epub 2011 Jun 23.

PMID:
21700622
21.

Emergence of KPC-producing Klebsiella pneumoniae in Texas.

Hirsch EB, Chang KT, Lasco TM, Caeiro JP, Tam VH.

Diagn Microbiol Infect Dis. 2011 Feb;69(2):234-5. doi: 10.1016/j.diagmicrobio.2010.09.003. No abstract available.

PMID:
21251574
22.

Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.

Skeiky YA, Dietrich J, Lasco TM, Stagliano K, Dheenadhayalan V, Goetz MA, Cantarero L, Basaraba RJ, Bang P, Kromann I, McMclain JB, Sadoff JC, Andersen P.

Vaccine. 2010 Jan 22;28(4):1084-93. doi: 10.1016/j.vaccine.2009.10.114. Epub 2009 Nov 5.

PMID:
19896449
23.

Cross-reaction of anti-human CD monoclonal antibodies on guinea pig cells: a summary of the guinea pig section of the HLDA8 animal homologues data.

Lasco TM, Gonzalez-Juarrero M, Saalmüller A, Lunney JK.

Vet Immunol Immunopathol. 2007 Sep 15;119(1-2):131-6. Epub 2007 Jun 20.

PMID:
17658620
24.

Mycobacterium bovis BCG vaccination modulates TNF-alpha production after pulmonary challenge with virulent Mycobacterium tuberculosis in guinea pigs.

Yamamoto T, Lasco TM, Uchida K, Goto Y, Jeevan A, McFarland C, Ly L, Yamamoto S, McMurray DN.

Tuberculosis (Edinb). 2007 Mar;87(2):155-65. Epub 2007 Feb 7.

PMID:
17289434
25.

Production and characterization of guinea pig recombinant gamma interferon and its effect on macrophage activation.

Jeevan A, McFarland CT, Yoshimura T, Skwor T, Cho H, Lasco T, McMurray DN.

Infect Immun. 2006 Jan;74(1):213-24.

26.

Vaccine-induced cytokine responses in a guinea pig model of pulmonary tuberculosis.

McMurray DN, Allen SS, Jeevan A, Lasco T, Cho H, Skwor T, Yamamoto T, McFarland C, Yoshimura T.

Tuberculosis (Edinb). 2005 Sep-Nov;85(5-6):295-301. Epub 2005 Oct 25.

PMID:
16253558
27.

Summary of the animal homologue section of HLDA8.

Saalmüller A, Lunney JK, Daubenberger C, Davis W, Fischer U, Göbel TW, Griebel P, Hollemweguer E, Lasco T, Meister R, Schuberth HJ, Sestak K, Sopp P, Steinbach F, Xiao-Wei W, Aasted B.

Cell Immunol. 2005 Jul-Aug;236(1-2):51-8. Epub 2005 Sep 29.

PMID:
16198325
28.

Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig.

Lasco TM, Cassone L, Kamohara H, Yoshimura T, McMurray DN.

Tuberculosis (Edinb). 2005 Jul;85(4):245-58. Epub 2005 Mar 3.

PMID:
15958260
30.

NIH pre-clinical screening program: overview and current status.

Izzo A, Brandt L, Lasco T, Kipnis AP, Orme I.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):25-8. Epub 2005 Jan 17. Review.

PMID:
15687024
31.

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.

Brandt L, Skeiky YA, Alderson MR, Lobet Y, Dalemans W, Turner OC, Basaraba RJ, Izzo AA, Lasco TM, Chapman PL, Reed SG, Orme IM.

Infect Immun. 2004 Nov;72(11):6622-32.

32.
33.

Rapid accumulation of eosinophils in lung lesions in guinea pigs infected with Mycobacterium tuberculosis.

Lasco TM, Turner OC, Cassone L, Sugawara I, Yamada H, McMurray DN, Orme IM.

Infect Immun. 2004 Feb;72(2):1147-9.

34.
35.

IroN, a novel outer membrane siderophore receptor characteristic of Salmonella enterica.

Bäumler AJ, Norris TL, Lasco T, Voight W, Reissbrodt R, Rabsch W, Heffron F.

J Bacteriol. 1998 Mar;180(6):1446-53.

Supplemental Content

Support Center